Medicaid patients continue high prescription opioid use after overdose
Staff Writer |
Despite receiving medical attention for an overdose, patients in Pennsylvania Medicaid continued to have persistently high prescription opioid use, with only slight increases in use of medication-assisted treatment, according to a study published by JAMA.
Article continues below
For every fatal opioid overdose, there are approximately 30 nonfatal overdoses. Nonfatal overdoses that receive medical attention represent intervention opportunities for clinicians to mitigate risk by reducing opioid prescribing or advocating addiction treatment.
Studies evaluating commercially insured patients suggest these potential interventions are underutilized. Julie M. Donohue, Ph.D., of the University of Pittsburgh Graduate School of Public Health, and colleagues used 2008-2013 claims data for all Pennsylvania Medicaid enrollees ages 12 to 64 years with a heroin or prescription opioid overdose to compare prescription opioid use, duration of opioid use, and rates of medication-assisted treatment (MAT; buprenorphine, methadone, or naltrexone) before and after an overdose event.
The analysis included 6,013 patients with an overdose event (2,068 with a heroin overdose and 3,945 with a prescription opioid overdose).
The researchers found that any filled opioid prescription decreased after overdose from 43.2% to 39.7% after heroin overdose, and from 66.1% before to 59.6% after prescription opioid overdose.
The%age of enrollees with 90 days or more duration of prescription opioids decreased in the heroin group (from 10.5% to 9%) and the prescription opioid group (from 32.5% to 28.3%). MAT increased after heroin overdose from 29.5% to 33% and after prescription opioid overdose from 13.5% to 15.1%.
The authors write that these findings indicate "a relatively weak health system response to a life-threatening event. Several interventions have been shown to reduce overdose risk, including trigger notifications to clinicians for patients treated for overdose and emergency department-initiated naloxone education and distribution."
Study limitations include the focus on one state and the use of claims data, which may underestimate opioid use by only tracking prescriptions filled. ■